Vitamin K (Phytomendione)

Brand Names: Canada

AquaMEPHYTON; Konakion; Mephyton

Pharmacologic Category

Vitamin, Fat Soluble

Dosing: Adult

Note: Oral route is more effective than the SubQ route in the treatment of nonbleeding patients with warfarin-associated coagulopathy; SubQ route has therefore fallen out of favor due to erratic and unpredictable absorption (Crowther 2002; DeZee 2006; Raj 1999). The IV route may be used in selected nonbleeding patients and should be used in patients with major bleeding due to warfarin-associated coagulopathy (ACCP [Guyatt 2012]; Patriquin 2011). IM route should be avoided due to the risk of hematoma formation.

Anticoagulant-induced prothrombin deficiency (caused by coumarin or indanedione derivatives):

Usual dosage range:

Oral: Initial: 2.5 to 10 mg (rarely up to 25 to 50 mg) as a single dose. May repeat in 12 to 48 hours if needed.

SubQ, IV: Initial: 2.5 to 10 mg (rarely up to 25 to 50 mg) as a single dose. Measure INR after 6 to 8 hours and repeat dose if needed.

Dosing based on INR and bleeding:

If INR above therapeutic range to <4.5 (no evidence of bleeding): Lower or hold next warfarin dose and monitor frequently; when INR approaches desired range, resume warfarin dosing with a lower dose (Patriquin 2011).

If INR 4.5 to 10 (no evidence of bleeding): The 2012 ACCP guidelines recommend against routine phytonadione (aka, vitamin K) administration in this setting (Guyatt 2012). Previously, the 2008 ACCP guidelines recommended if no risk factors for bleeding exist, to omit next 1 or 2 warfarin doses, monitor INR more frequently, and resume with an appropriately adjusted warfarin dose when INR in desired range; may consider administering vitamin K orally 1 to 2.5 mg if other risk factors for bleeding exist (Hirsh 2008). Others have recommended consideration of vitamin K 1 mg orally or 0.5 mg IV (Patriquin 2011).

If INR >10 (no evidence of bleeding): The 2012 ACCP guidelines recommend administration of oral vitamin K (dose not specified) in this setting (Guyatt 2012). Previously, the 2008 ACCP guidelines recommended to hold warfarin, administer vitamin K orally 2.5 to 5 mg, expect INR to be reduced within 24 to 48 hours, monitor INR more frequently and give additional vitamin K at an appropriate dose if necessary; resume warfarin at an appropriately adjusted dose when INR is in desired range (Hirsh 2008). Others have recommended consideration of vitamin K 2 to 2.5 mg orally or 0.5 to 1 mg IV (Patriquin 2011).

If minor bleeding at any INR elevation: Hold warfarin, may administer vitamin K orally 2.5 to 5 mg, monitor INR more frequently, may repeat dose after 24 hours if INR correction incomplete; resume warfarin at an appropriately adjusted dose when INR is in desired range (Patriquin 2011).

If major bleeding at any INR elevation: The 2012 ACCP guidelines recommend administration of four-factor prothrombin complex concentrate (PCC) and IV vitamin K 5 to 10 mg in this setting (Guyatt 2012). The only available four-factor PCC in the US is Kcentra. Other four-factor PCCs not available in the US include Beriplex P/N, Cofact, and Octaplex. Bebulin VH and Profilnine SD do not contain adequate levels of factor VII and are considered three-factor PCCs. Previously, the 2008 ACCP guidelines recommended to hold warfarin, administer vitamin K 10 mg by slow IV infusion and supplement with PCC depending on the urgency of the situation; IV vitamin K may be repeated every 12 hours (Hirsh 2008).

Note: Use of high doses of vitamin K (eg, 10 to 15 mg) may cause warfarin resistance for ≥1 week. During this period of resistance, heparin or low-molecular-weight heparin (LMWH) may be given until INR responds (Ansell 2008).

Hypoprothrombinemia due to drugs (other than coumarin derivatives) or factors limiting absorption or synthesis:

Oral: Initial: 2.5 to 25 mg (rarely up to 50 mg)

SubQ, IV: Initial: 2.5 to 25 mg (rarely up to 50 mg). Measure INR after 6 to 8 hours and repeat dose if needed.

Acute liver failure coagulopathy: SubQ, IV: 5 to 10 mg (at least one dose) (AASLD [Lee 2011]; Pereira 2005)

Preprocedural/surgical INR normalization in patients receiving warfarin (routine use): Oral: 1 to 2.5 mg once administered on the day before surgery; recheck INR on day of procedure/surgery (Douketis 2012). Others have recommended the use of vitamin K 1 mg orally for mild INR elevations (ie, INR 3.0 to 4.5) (Patriquin 2011).

Intracranial hemorrhage associated with vitamin K antagonist anticoagulants (eg, warfarin) (off-label use): IV: Initial: 10 mg once given as soon as possible and concomitantly with 4-factor prothrombin complex concentrate (PCC) for INR ≥1.4 (3-factor PCC may be given concomitantly with phytonadione but 4-factor PCC is preferred). Subsequent phytonadione administration is guided by follow-up INR; if subsequent INR ≥1.4 within the first 24 to 48 hours after the initial dose, give a repeat dose of phytonadione 10 mg IV (NCS/SCCM [Frontera 2016]).

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Pediatric

Note: Route of administration varies with indication; careful evaluation of route of administration is important. The oral route is preferred in the treatment of nonbleeding patients with warfarin-associated coagulopathy; SubQ administration has fallen out of favor for this indication due to erratic and unpredictable absorption (Crowther 2002; DeZee 2006; Raj 1999). The IV route may be used in select nonbleeding patients and should be used in patients with major bleeding due to warfarin-associated coagulopathy (Bolton-Maggs 2002; CHEST [Monagle 2012]). The IV and SubQ routes may be used in the treatment of vitamin K deficiency bleeding (Kliegman 2016). The IM route should be avoided due to the risk of hematoma formation except in the prevention/treatment of vitamin K deficiency bleeding (Kliegman 2016). Dosing presented in mcg and mg; verify dosing units.

Vitamin K deficiency, prevention, and supplementation (Disease-specific): Limited data available:

Biliary atresia (Shneider 2012): Note: Dose and route are determined by INR value: Infants 1 to 6 months:

INR >1.2 to 1.5: 2.5 mg once daily orally

INR >1.5 to 1.8: Initial: 2 to 5 mg IM once followed by 2.5 mg once daily orally

INR >1.8: Initial: 2 to 5 mg IM once followed by 5 mg once daily orally

Cholestasis: Infants, Children, and Adolescents: Oral: 2.4 to 15 mg/day (Sathe 2010)

Cystic fibrosis: Infants, Children, and Adolescents: Oral: 0.3 to 0.5 mg/day (Borowitz 2002; Sathe 2010)

Liver disease: Infants, Children, and Adolescents: Oral: 2.5 to 5 mg/day (Nightingale 2009; Sathe 2010)

Reversal of Vitamin K antagonists (eg, warfarin): Limited data available: Infants, Children, and Adolescents:

Weight-based dosing (preferred): Chest recommendations: IV: 0.03 mg/kg/dose is recommended for excessively prolonged INR (usually INR >8; no evidence of bleeding) due to vitamin K-antagonist (eg, warfarin): if significant bleeding, consider use of fresh frozen plasma, prothrombin complex concentrates, or recombinant factor VIIa (Bolton-Maggs 2002; Monagle 2012)

Alternate dosing: Fixed dosing: Note: Smaller pediatric patients should receive doses on the low end of dosing range; excessive dosages may cause warfarin-resistance (Bolton-Maggs 2002; Michelson 1998)

No bleeding, rapid reversal needed, patient will require further oral anticoagulant therapy: SubQ, IV: 0.5 to 2 mg

No bleeding, rapid reversal needed, patient will not require further oral anticoagulant therapy: SubQ, IV: 2 to 5 mg

Significant bleeding, not life-threatening: SubQ, IV: 0.5 to 2 mg

Significant bleeding, life-threatening: SubQ, IV: 5 mg

Parenteral nutrition, maintenance requirement: Limited data available (Vanek 2012): IV: Note: Patients receiving warfarin may not require TPN supplementation of phytonadione.

Infants: 10 mcg/kg/day

Children and Adolescents: 200 mcg/day

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in manufacturer’s labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in manufacturer’s labeling; dosing adjustment unlikely necessary.

Use: Labeled Indications

Anticoagulant-induced prothrombin deficiency: Treatment of anticoagulant-induced prothrombin deficiency caused by coumarin or indandione derivatives

Vitamin K deficiency bleeding (formerly known as hemorrhagic disease) of the newborn: Prophylaxis and therapy of vitamin K deficiency bleeding (formerly known as hemorrhagic disease) of the newborn (injection only)

Hypoprothrombinemia: Hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K (eg, obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, regional enteritis), and other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism (eg, salicylates, antibacterial therapy)

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Hypoprothrombinemia due to long-acting anticoagulant rodenticides (LAARs)Level of Evidence [C]

Data from a few case reports suggest that phytonadione may be beneficial in the treatment of hypoprothrombinemia caused by long-acting anticoagulant rodenticides (brodifacoum) Ref. Data from a limited number of patients (case series) also suggest that phytonadione may be beneficial in this setting Ref. Additional data may be necessary to further define the role of phytonadione in the treatment of this condition.

Intracranial hemorrhage associated with vitamin K antagonist anticoagulants (eg, warfarin)Level of Evidence [G]

Based on the Neurocritical Care Society and the Society of Critical Care Medicine guideline for reversal of antithrombotics in intracranial hemorrhage, phytonadione, with 4-factor prothrombin complex concentrate (PCC), is recommended as soon as possible for vitamin K antagonist-associated intracranial hemorrhage and INR ≥1.4. Three-factor PCC may be given with phytonadione but 4-factor PCC is preferred Ref.

Level of Evidence Definitions

Level of Evidence Scale

Clinical Practice Guidelines

Life-Threatening Hemorrhage:

ACC, “2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants” December 2017

NCS/SCCM, “Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage,” 2016

Stroke:

AHA/ASA, “Guidelines for the Management of Spontaneous Intracerebral Hemorrhage,” July 2015

Other:

American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition), February 2012

Administration: IM

IM route should be avoided due to the risk of hematoma formation.

Administration: IV

Infuse slowly; rate of infusion should not exceed 1 mg/minute. Alternatively, dilute dose in a minimum of 50 mL of compatible solution and administer using an infusion pump over at least 20 minutes (Ageno, 2012). The injectable route should be used only if the oral route is not feasible or there is a greater urgency to reverse anticoagulation. The IV route may be used in selected nonbleeding patients and should be used in patients with major bleeding due to warfarin-associated coagulopathy (ACCP [Guyatt 2012]; Patriquin 2011).

Administration: Injectable Detail

pH: 3.5 to 7

Administration: Oral

The parenteral formulation may also be used for small oral doses (eg, 1 mg) or situations in which tablets cannot be swallowed (Crowther 2000; Crowther 2002; O’Connor 1986); may administer undiluted or diluted in a beverage (eg, orange juice) (Vanier 2006).

Administration: Subcutaneous

SubQ route has fallen out of favor due to erratic and unpredictable absorption (Crowther 2002; DeZee 2006; Raj 1999).

Administration: Pediatric

Oral: May be administered with or without food. The parenteral formulation may also be used for small oral doses (eg, 1 mg) or situations in which tablets cannot be swallowed (Crowther 2000; O'Connor 1986).

Parenteral: Note: Limit IV administration to situations where an alternative route of administration is not feasible and the benefit of therapy outweighs the risk of hypersensitivity reactions; proper dosing, dilution, and administration will minimize risk (Ageno 2012; Riegert-Johnson 2002). Allergic reactions have also occurred with IM and SubQ injections, albeit less frequently.

SubQ: Administer undiluted.

IM: Administer undiluted; for use in neonatal patients, verify appropriate concentration (1 mg/0.5 mL)

IV: After dilution, infuse slowly. In pediatric patients, IV doses have been infused over 15 to 30 minutes (Kliegman 2007; Michelson 1998); maximum rate of infusion: 1 mg/minute

Dietary Considerations

Dietary adequate intake (IOM 2001; Vanek 2012):

1 to 6 months: 2 mcg/day

7 to 12 months: 2.5 mcg/day

1 to 3 years: 30 mcg/day

4 to 8 years: 55 mcg/day

9 to 13 years: 60 mcg/day

14 to 18 years: 75 mcg/day

>18 years: Males: 120 mcg/day; Females: 90 mcg/day

Storage/Stability

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.

Preparation for Administration: Adult

Dilute injection solution in preservative-free NS, D5W, or D5NS. To reduce the incidence of anaphylactoid reaction upon IV administration, dilute dose in a minimum of 50 mL of compatible solution and administer using an infusion pump over at least 20 minutes (Ageno, 2012).

Preparation for Administration: Pediatric

Parenteral: IV: Dilute phytonadione injection in preservative-free NS, D5W, or D5NS. To reduce the incidence of anaphylactoid reaction upon IV administration dilution of dose is recommended (eg, in adults, dilution of the dose in a minimum of 50 mL of compatible solution has been used) (Ageno 2012).

Extemporaneously Prepared

A 1 mg/mL oral suspension may be made with tablets. Crush six 5 mg tablets in a mortar and reduce to a fine powder. Add 5 mL each of water and methylcellulose 1% and mix to a uniform paste. Mix while adding sorbitol in incremental proportions to almost 30 mL; transfer to a calibrated bottle, rinse mortar with sorbitol, and add quantity of sorbitol sufficient to make 30 mL. Label "shake well" and "refrigerate". Stable for 3 days.

Nahata MC and Hipple TF, Pediatric Drug Formulations, 3rd ed, Cincinnati, OH: Harvey Whitney Books Co, 1997.

Note: The parenteral formulation may also be used for small oral doses (eg, 1 mg) or situations in which tablets cannot be swallowed (Crowther, 2000; O’Connor, 1986); may administer undiluted or diluted in a beverage (eg, orange juice) (Vanier 2006).

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to replace low vitamin K, to undo the effects of certain blood thinners like warfarin, and to treat or prevent bleeding. It is often given to newborn babies.

Frequently reported side effects of this drug

• Injection site pain

• Edema

• Irritation

• Change in taste

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Flushing

• Skin reaction

• Chest pain

• Fast heartbeat

• Loss of strength and energy

• Abnormal heartbeat

• Dizziness

• Passing out

• Shortness of breath

• Sweating a lot

• Blue/gray skin discoloration

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Contraindications

Hypersensitivity to phytonadione or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Dermatologic toxicity: Cutaneous reactions have occurred after parenteral administration, including delayed-type hypersensitivity reactions, eczematous reactions, scleroderma-like patches, and urticaria; onset may occur within 1 day to a year. If skin reactions occur, discontinue therapy and treat appropriately.

• Hypersensitivity/anaphylactoid reactions: [US Boxed Warning]: Fatal hypersensitivity reactions, including anaphylaxis, have occurred with parenteral use; onset may occur during or immediately after intravenous (IV) or intramuscular (IM) administration. Reactions have occurred despite dilution to avoid rapid IV infusion and with the first dose. Avoid IV and IM administration unless subcutaneous administration is not feasible and the serious risk is justified. Anaphylactoid reactions typically occurred when patients received large IV doses administered rapidly with formulations containing polyethoxylated castor oil (also called polyoxyethylated castor oil); proper dosing, dilution, and administration will minimize risk (Ageno 2012; Riegert-Johnson 2002).

Disease-related concerns:

• Anticoagulant-induced hypoprothrombinemia: In patients receiving a therapeutic vitamin K antagonist (VKA) (eg, warfarin), administer a dose of phytonadione that will quickly lower the INR into a safe range without causing resistance to warfarin. High phytonadione doses may lead to warfarin resistance for at least one week.

• Liver disease induced hypoprothrombinemia: If initial doses do not reverse coagulopathy, then higher doses are unlikely to have any effect. Note: Ineffective in hereditary hypoprothrombinemia.

• Long-acting anticoagulant rodenticide (LAAR) ingestion: Patients with LAAR-induced coagulopathy require much larger doses and longer treatment durations (up to months) after exposure compared to that needed to reverse warfarin-induced coagulopathy.

Special populations:

• Neonates: Use with caution in neonates, especially premature infants; severe hemolytic anemia, jaundice, and hyperbilirubinemia have been reported with larger than recommended doses (10 to 20 mg).

Dosage form specific issues:

• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.

• Polyoxyethylated castor oil: Some injectable dosage forms contain polyoxyethylated castor oil (Cremophor EL) which is associated with hypersensitivity reactions.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

Other warnings/precautions:

• Appropriate route: Oral administration is the safest and requires the presence of bile salts for absorption. In obstructive jaundice or with biliary fistulas, concurrent administration of bile salts would be necessary for proper absorption. Manufacturers recommend the SubQ route over other parenteral routes, however, SubQ is less predictable when compared to the oral route, and efficacy may be delayed. Therefore, the SubQ route has fallen out of favor due to erratic and unpredictable absorption (Crowther 2002; DeZee 2006; Raj 1999). The IV route may be used in selected nonbleeding patients and should be used in patients with major bleeding due to warfarin-associated coagulopathy (ACCP [Guyatt 2012]; Patriquin 2011). IM route should be avoided due to the risk of hematoma formation (except, for example, in the neonatal and pediatric populations for prevention/treatment of vitamin K deficiency bleeding). Efficacy (eg, control of bleeding, decrease in INR) is delayed regardless of route of administration; patient management may require other treatments in the interim.

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

No special recommendation for use or dosing in elderly.

Pregnancy Considerations

Phytonadione crosses the placenta in limited concentrations (Kazzi 1990).

The dietary requirements of vitamin K are the same in pregnant and nonpregnant women (IOM 2000). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Use of preservative free solutions are preferred when the injection is needed during pregnancy.

Breast-Feeding Considerations

Phytonadione is present in breast milk.

Small amounts of dietary vitamin K can be detected in breast milk and the dietary requirements of vitamin K are the same in breastfeeding and non-breastfeeding women (IOM 2000). According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Use of preservative free solutions are preferred when the injection is needed in breastfeeding women.

Briggs' Drugs in Pregnancy & Lactation

• Phytonadione

Adverse Reactions

Frequency not defined:

Cardiovascular: Chest pain, flushing, hypotension, tachycardia, weak pulse

Central nervous system: Dizziness

Dermatologic: Diaphoresis, eczematous rash, erythema, erythematous rash, pruritic plaques of the skin, urticaria

Gastrointestinal: Dysgeusia

Hepatic: Hyperbilirubinemia

Hypersensitivity: Anaphylactoid reaction, anaphylaxis, hypersensitivity reaction

Local: Injection site reaction (including pain, swelling, tenderness)

Respiratory: Cyanosis, dyspnea

Miscellaneous: Lesion (scleroderma-like)

* See Cautions in AHFS Essentials for additional information.

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

Mineral Oil: May decrease the serum concentration of Phytonadione. Specifically, mineral oil may decrease the absorption of phytonadione. Risk C: Monitor therapy

Orlistat: May decrease the serum concentration of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat. Similar precautions do not apply to parenterally administered fat soluble vitamins. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Phytonadione may diminish the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Genes of Interest

• Vitamin K Epoxide Reductase Complex, Subunit 1

Monitoring Parameters

PT, INR; monitor for hypersensitivity reactions if administering IV.

Advanced Practitioners Physical Assessment/Monitoring

Obtain PT/INR and assess the degree of bleeding. Assess patient closely for severe hypersensitivity reactions if administering IV; subcutaneous administration recommended.

Nursing Physical Assessment/Monitoring

Check ordered labs and report abnormalities. Monitor for hypersensitivity reactions if administering IV; subcutaneous administration is recommended to avoid risk of fatal hypersensitivity reactions.

Dosage Forms Considerations

Injectable products may contain alcohol, benzyl alcohol, polysorbate 80, propylene glycol, or polyoxyethylated/polyethoxylated castor oil (Cremophor EL).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Injection, aqueous colloidal: 1 mg/0.5 mL (0.5 mL); 10 mg/mL (1 mL)

Injection, aqueous colloidal [preservative free]: 1 mg/0.5 mL (0.5 mL)

Tablet, oral:

Mephyton: 5 mg [scored]

Generic: 100 mcg, 5 mg

Anatomic Therapeutic Chemical (ATC) Classification

• B02BA01

Generic Available (US)

Yes

Pricing: US

Capsules (K1-1000 Oral)

1 mg (per each): $0.11

Solution (Phytonadione Injection)

1 mg/0.5 mL (per 0.5 mL): $27.00

10 mg/mL (per mL): $51.32

Tablets (Mephyton Oral)

5 mg (per each): $70.51

Tablets (Phytonadione Oral)

5 mg (per each): $66.99

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Promotes liver synthesis of clotting factors (II, VII, IX, X); however, the exact mechanism as to this stimulation is unknown. Menadiol is a water soluble form of vitamin K; phytonadione has a more rapid and prolonged effect than menadione; menadiol sodium diphosphate (K4) is half as potent as menadione (K3).

Pharmacodynamics/Kinetics

Onset of action: Increased coagulation factors: Oral: 6 to 10 hours; IV: 1 to 2 hours

Peak effect: INR values return to normal: Oral: 24 to 48 hours; IV: 12 to 14 hours

Absorption: Oral: From intestines in presence of bile; SubQ: Variable; IM: Readily

Metabolism: Rapidly hepatic

Excretion: Urine and feces

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: Abnormal taste.

Effects on Bleeding

Phytonadione is a synthetic form of vitamin K and has been used as an antidote to reverse warfarin-induced bleeding complications or endogenous vitamin K deficiencies.

Related Information

• Reversal of Oral Anticoagulants

Index Terms

Methylphytyl Napthoquinone; Phylloquinone; Phytomenadione; Vitamin K; Vitamin K1

FDA Approval Date

September 30, 1955

References

Ageno W, Gallus AS, Wittkowsky A, et al, “Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, 2012, 141(2 Suppl):e44-88.[PubMed 22315269]

Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319.[PubMed 11487763]

Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.[PubMed 3960626]

Aluminum in large and small volume parenterals used in total parenteral nutrition. Fed Regist. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.

American Academy of Pediatrics Committee on Fetus and Newborn, "Controversies Concerning Vitamin K and the Newborn. American Academy of Pediatrics Committee on Fetus and Newborn," Pediatrics, 2003, 112(1 Pt 1):191-2.[PubMed 12837888]

American Academy of Pediatrics, Committee on Nutrition. Pediatric Nutrition Handbook, 7th ed, Kleinman RE, Greer FR, eds, Elk Grove Village, IL: American Academy of Pediatrics; 2013, 510-515.

American Academy of Pediatrics Committee on Nutrition, "Micronutrients: Vitamin K," Pediatric Nutrition Handbook, 6th ed, Kleinman RE, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 469.

Andersen P and Godal HC, “Predictable Reduction in Anticoagulant Activity of Warfarin by Small Amounts of Vitamin K,” Acta Med Scand, 1975, 198:269-70.[PubMed 1189983]

Ansell J, Hirsh J, Hylek E, et al, “Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),” Chest, 2008, 133(6 Suppl):160-98.[PubMed 18574265]

Aquamephyton (phytonadione) [prescribing information]. Buena, NJ: Teligent Pharma; March 2018.

Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? Birth Defects Res A Clin Mol Teratol. 2003;67(2):133-140.[PubMed 12769509]

Barash P, Kitahata LM, and Mandel S, “Acute Cardiovascular Collapse After Intravenous Phytonadione,” Anesth Analg, 1976, 55(2):304-6.[PubMed 943998]

Bolton-Maggs P and Brook L. “The Use of Vitamin K for Reversal of Over-Warfarinization In Children,” Br J Haematol, 2002, 118(3):924.[PubMed 12181071]

Borowitz D, Baker RD, and Stallings V, "Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis," J Pediatr Gastroenterol Nutr, 2002, 35(3):246-59.[PubMed 12352509]

Bruno GR, Howland MA, McMeeking A, et al, “Long-Acting Anticoagulant Overdose: Brodifacoum Kinetics and Optimal Vitamin K Dosing,” Ann Emerg Med, 2000, 36(3):262-7.[PubMed 10969235]

Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm[PubMed 6810084]

Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm.[PubMed 6423951]

Chua JD and Friedenberg WR, “Superwarfarin Poisoning,” Arch Intern Med, 1998, 158(17):1929-32.[PubMed 9759690]

Clarke P, Mitchell SJ, Wynn R, et al, "Vitamin K Prophylaxis for Preterm Infants: A Randomized, Controlled Trial of 3 Regimens," Pediatrics, 2006, 118(6):e1657-66.[PubMed 17101711]

Costakos DT, Greer FR, Love LA, et al, "Vitamin K Prophylaxis for Premature Infants: 1 mg Versus 0.5 mg," Am J Perinatol, 2003, 20(8):485-90.[PubMed 14703597]

Costakos DT, Porte M. Did "controversies concerning vitamin K and the newborn" cover all the controversies? Pediatrics. 2004;113(5):1466-1467.[PubMed 15121973 ]

Crowther MA, Douketis JD, Schnurr T, et al, "Oral Vitamin K Lowers the International Normalized Ratio More Rapidly Than Subcutaneous Vitamin K in the Treatment of Warfarin-Associated Coagulopathy. A Randomized, Controlled Trial," Ann Intern Med, 2002, 137(4):251-4.[PubMed 12186515]

Crowther MA, Julian J, McCarty D, et al, “Treatment of Warfarin-associated Coagulopathy With Oral Vitamin K: A Randomised Controlled Trial”, Lancet, 2000, 356(9241):1551-3.[PubMed 11075768]

Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'Malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med. 2006;166(4):391-397. doi: 10.1001/.391.[PubMed 16505257]

Douketis JD, Spyropoulos AC, Spencer FA, et al, “Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, 2012, 141(2 Suppl):326-50.[PubMed 22315266]

Fiore LD, Scola MA, Cantillon CE, et al, "Anaphylactoid Reactions to Vitamin K," J Thromb Thrombolysis, 2001, 11(2): 175-83.

Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6-46.[PubMed 26714677]

Gunja N, Coggins A, and Bidny S, “Management of Intentional Superwarfarin Poisoning With Long-Term Vitamin K and Brodifacoum Levels,” Clin Toxicol, 2011, 49(5):385-90.[PubMed 21740137]

Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, 2012, 141(2 Suppl):7-47.[PubMed 22315257]

Harrell CC and Kline SS, “Oral Vitamin K1: An Option to Reduce Warfarin's Activity,” Ann Pharmacother, 1995, 29(12):1228-32.

Hirsh J, Guyatt G, Albers GW, et al, “Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),” Chest, 2008, 133(6 Suppl):71-109.[PubMed 18574259]

Hopkins CS, “Adverse Reaction to a Cremophor-Containing Preparation of Intravenous Vitamin K,” Intensive Therapy Clin Monit, 1988, 9:254-5.

"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278.[PubMed 9024461]

IOM (Institute of Medicine), Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc, Washington, DC: National Academy Press, 2000.

Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313.[PubMed 12534540]

Kazzi NJ, Ilagan NB, Liang KC, Kazzi GM, Grietsell LA, Brans YW. Placental transfer of vitamin K1 in preterm pregnancy. Obstet Gynecol. 1990 Mar;75(3 Pt 1):334-337.[PubMed 2304704]

Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. Nelson' s Textbook of Pediatrics. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.

Lee WM, Stravitz T, Larson AM. AASLD Position Paper: The management of acute liver failure: update 2011. http://aasld.org/sites/default/files/guideline_documents/AcuteLiverFailureUpdate201journalformat1.pdf.

Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172.[PubMed 10985636]

Martinez-Abad M, Delgado F, Palop V, et al, “Vitamin K1 and Anaphylactic Shock,” DICP, 1991, 25(7-8):871-2.

Mephyton (phytonadione) [prescribing information]. Lawrenceville, NJ: Aton Pharma; November 2016.

Michelson AD, Bovill E, Monagle P, et al, “Antithrombic Therapy in Children,” Chest, 1998, 114(5 Suppl):748-69.[PubMed 9822076]

Monagle P, Chan A, Goldenberg NA, et al, "Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition)," Chest, 2012, 141(2 Suppl):e737-801.[PubMed 22315277]

Nightingale S and Ng VL, "Optimizing Nutritional Management in Children With Chronic Liver Disease," Pediatr Clin North Am, 2009, 56(5):1161-83.[PubMed 19931069]

Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.[PubMed 24589852]

O’Connor ME and Addiego JE, “Use of Oral Vitamin K1 to Prevent Hemorrhagic Disease of the Newborn Infant,” J Pediatr, 1986, 108(4):616-9.[PubMed 3514830]

Olmos V and Lopez CM, “Brodifacoum Poisoning with Toxicokinetic Data,” Clin Toxicol, 2007, 45(5):487-9.[PubMed 17503253]

Patriquin C and Crowther M, “Treatment of Warfarin-associated Coagulopathy With Vitamin K,” Expert Rev Hematol, 2011, 4(6):657-67.

Pereira SP, Rowbotham D, Fitt S, Shearer MJ, Wendon J, Williams R. Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease. J Hepatol. 2005;42(3):365-370.[PubMed 15710219]

Phytonadione [prescribing information]. El Monte, CA: International Medication Systems, Limited; December 2017.

Phytonadione injectable emulsion [prescribing information]. Princeton, NJ: Dr. Reddy's Laboratories Inc; May 2019.

Phytonadione Injection [prescribing information]. North Chicago, IL: Abbott Laboratories; August 2002.

Phytonadione Injection [prescribing information]. Lake Forest, IL: Hospira, Inc; April 2018.

Phytonadione Injection [prescribing information]. Zanesville, OH: Cardinal Health; November 2004.

Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione [published correction appears in: Arch Intern Med. 2000;160(7):986]. Arch Intern Med. 1999;159(22):2721-2724.[PubMed 10597763]

Riegert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol. 2002;89(4):400-406.[PubMed 12392385]

Sathe MN and Patel AS, "Update in Pediatrics: Focus on Fat-Soluble Vitamins," Nutr Clin Pract, 2010, 25(4):340-6.[PubMed 20702838]

Shearer MJ, “Vitamin K,” Lancet, 1995, 345(8944):229-34.[PubMed 7823718]

Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259.[PubMed 19188870]

Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.[PubMed 7746084]

Shneider BL, Magee JC, Bezerra JA, et al, "Efficacy of Fat-Soluble Vitamin Supplementation in Infants With Biliary Atresia," Pediatrics, 2012, 130(3):e607-14.[PubMed 22891232]

Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(24):3042-3067. doi: 10.1016/j.jacc.2017.09.1085.[PubMed 29203195]

Vanek VW, Borum P, Buchman A, et al, "A.S.P.E.N. Position Paper: Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi-trace Element Products," Nutr Clin Pract, 2012, 27(4):440-91.[PubMed 22730042]

Vanier MC and Ngo TT. Reversal of overanticoagulation with vitamin K1: A plea for oral administration. Can J Hosp Pharm. 2006;59:125-135.

Watt BE, Proudfoot AT, Bradberry SM, et al, "Anticoagulant Rodenticides," Toxicol Rev, 2005, 24(4):259-69.[PubMed 16499407]

Weibert RT, Le DT, Kayser SR, et al, "Correction of Excessive Anticoagulation With Low-Dose Oral Vitamin K1," Ann Intern Med, 1997, 126(12):959-62.[PubMed 9182473]

Brand Names: International

Bonadiona (CR, DO, GT, HN, NI, PA, SV); Dynaphyto (PH); Haemokion (AE, CY, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE); Hema-K (PH); Hematron (PH); Kanakion (PT); Kanavit (CZ); Katimin-1 (TW); Kenadion (IN); Konakion (10 mg) (AE, AU, BG, CY, DE, EC, GB, GH, IE, IL, IQ, IR, IT, JO, KE, KW, LB, LY, NL, OM, SA, SE, SY, TZ, UG, YE, ZM); Konakion (BE, DK, ES, HU, IS, LU, NO, SI, TR, ZW); Konakion 10 mg (AT, FI, HN); Konakion MM (BH, CL, HR, KW, LB, LK, LV, MX); Konakion MM Paediatric (BB, BM, BS, BZ, GY, JM, SR, TT); Konakion MM Pediatric (AR, AU, BR, CH, CO, NZ, PE, PK, PY, UY, VN); Mepro K (ID); Neokay (GB); Phytomen (PH); Prohem (ID); Univitan K1 (HK); Vitacon (PL); Vitak (JP); Vitamin K (HK); Vitamin K1 (KR); Vitamine K!1 Roche (FR); Vitka Infant (ID)

Last Updated 3/28/20